Home > Healthcare > Medical Devices > Diagnostic Devices > Sepsis Diagnostics Market

Sepsis Diagnostics Market Trends

Report ID: GMI5899
Published Date: May 2023
Report Format: PDF

Download Free Sample

Sepsis Diagnostics Market Trends

Advances in sepsis diagnosis have been a major driving force in the sepsis diagnostics industry. Furthermore, an increase in the prevalence of sepsis and growth in the worldwide geriatric population base is attributed to an increase in the demand for sepsis diagnostics. Additionally, an increase in government funding for sepsis-related research efforts, as well as an increase in the incidence of infectious ailments, are predicted to accelerate market trends.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

The global market for sepsis diagnostics was worth more than USD 620 million in 2022 and is estimated to generate more than USD 1.2 billion by 2032 driven by the rising incidence of hospital-acquired infections, expanding geriatric population base, and chronic illness patients.

The blood culture media product segment amassed approximately USD 224 million in 2022 and is projected to grow at a robust CAGR through 2032 owing to the rising product demand due to their cost-effectiveness and convenience.

North America held a notable revenue share in the sepsis diagnostics market and is set to exhibit a steady growth rate attributed to the presence of highly developed healthcare systems and the implementation of innovative sepsis diagnostic technologies.

The leading companies engaged in the sepsis diagnostics industry are Abbott Laboratories, BioMerieux SA, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, Bruker Corporation, Beckman Coulter, Inc., T2 Biosystems, Inc., Nanosphere, Inc., Hoffmann-LA Roche Ltd., Danaher Corporation